Prosecution Insights
Last updated: April 18, 2026
Application No. 17/623,144

PROTEIN-ENCLOSING POLYMERIC MICELLE

Final Rejection §102§103§112
Filed
Dec 27, 2021
Examiner
CHANDRA, GYAN
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The University of Tokyo
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
2y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
695 granted / 978 resolved
+11.1% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
38 currently pending
Career history
1016
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
29.5%
-10.5% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
29.5%
-10.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 978 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response filed on 11/12/2025 is acknowledged and fully considered. Status of Application, Amendments, And/Or Claims The amendments of claim 1, 4, 8 and 11 have been made of record. Claims 1-11 are pending and under consideration. Information Disclosure Statement The Information Disclosure Statements (IDSs) filed on 7/9/2025, 8/14/2025 and 11/12/2025 have been considered. Response to Arguments Claim Rejections - 35 USC § 102-withdrawn The rejection of claim(s) 1-4 and 7-11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sakurai et al. (US Pub. No. 200200822198 A1) is withdrawn in view of applicant’s amendments to claim 1 where applicants amend the term “m2 represents an integer greater than 0 up to 500”. However, the instant amendments introduce a new matter that is not supported by the instant specification and the claims would be rejected under a New Matter Rejection. It is noted to applicants that if the instant claims are amended back to the previous form, then the previous rejection would be reinstated. Claim Rejections - 35 USC § 103-withdrawn The rejection of claims 1-11 under 35 U.S.C. 103 as being unpatentable over Sakurai et al. (US Pub. No. 200200822198 A1) in view of Xu et al. (IDS, International J. of Nanomedicine 2018, 13:7229-7249) are withdrawn in view of applicant’s amendments to claim 1 where applicants amend the term “m2 represents an integer greater than 0 up to 500”. However, the instant amendments introduce a new matter that is not supported by the instant specification and the claims would be rejected under a New Matter Rejection. It is noted to applicants that if the instant claims are amended back to the previous form, then the previous rejection would be reinstated. New Ground of Rejection Necessitated by Applicant’s amendments Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-11 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. THIS IS A NEW MATTER REJECTION. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The new claims are not described in the Specification or the Claims as originally filed. The proscription against the introduction of new matter in a patent application (35 U.S.C. 132 and 251) serves to prevent an applicant from adding information that goes beyond the subject matter originally filed. See In re Rasmussen, 650 F.2d 1212, 1214, 211 USPQ 323, 326 (CCPA 1981). See MPEP § 2163.06 through § 2163.07 for a more detailed discussion of the written description requirement and its relationship to new matter. The claims as filed in the original specification are part of the disclosure and, therefore, if an application as originally filed contains a claim disclosing material not found in the remainder of the specification, the applicant may amend the specification to include the claimed subject matter. In re Benno, 768 F.2d 1340, 226 USPQ 683 (Fed. Cir. 1985). Thus, the written description requirement prevents an applicant from claiming subject matter that was not adequately described in the specification as filed. New or amended claims which introduce elements or limitations which are not supported by the as-filed disclosure violate the written description requirement. See, e.g., In re Lukach, 442 F.2d 967, 169 USPQ 795 (CCPA 1971) (subgenus range was not supported by generic disclosure and specific example within the subgenus range); In re Smith, 458 F.2d 1389, 1395, 173 USPQ 679, 683 (CCPA 1972) (a subgenus is not necessarily described by a genus encompassing it and a species upon which it reads). While there is no in haec verba requirement, newly added claim limitations must be supported in the specification through express, implicit, or inherent disclosure. MPEP 2105. In the instant application, there is no support in the specification, as originally filed, for the claim limitation “ wherein m2 is an integer greater than 0”. The specification on page 3 discloses that m1 and m2 each independently represent an integer of 0 to 500 (provided that the sum of m1 and m2 represents an integer of 10 to 500). The specification does not explicitly or implicitly say that m2 is greater than 0. If m1 is 10 then m2 would be 0 and still meets the limitation of m1+m2 as total 10. Therefore, claims 1-11 are rejected under 35 USC 112, first paragraph-new matter. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GYAN CHANDRA whose telephone number is (571)272-2922. The examiner can normally be reached Mon-Friday 8:30AM-5:00P. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GYAN CHANDRA/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Dec 27, 2021
Application Filed
May 09, 2025
Non-Final Rejection — §102, §103, §112
Nov 12, 2025
Response Filed
Dec 26, 2025
Final Rejection — §102, §103, §112
Feb 27, 2026
Interview Requested
Mar 11, 2026
Examiner Interview Summary
Mar 30, 2026
Request for Continued Examination
Apr 01, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600758
INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
2y 5m to grant Granted Apr 14, 2026
Patent 12600771
ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR
2y 5m to grant Granted Apr 14, 2026
Patent 12594323
METHODS OF REDUCING NEUROINFLAMMATION
2y 5m to grant Granted Apr 07, 2026
Patent 12589142
HLA TUMOR ANTIGEN PEPTIDES OF CLASS I AND II FOR TREATING MAMMARY/BREAST CARCINOMAS
2y 5m to grant Granted Mar 31, 2026
Patent 12576136
Insulin Derivative
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+27.5%)
2y 9m
Median Time to Grant
Moderate
PTA Risk
Based on 978 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month